Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Thorax. 2012 Oct;67(10):882–890. doi: 10.1136/thoraxjnl-2012-202550

Figure 1.

Figure 1

Cystic fibrosis transmembrane conductance regulator gene mutation classes and therapeutic approaches under study by the cystic fibrosis Therapeutics Development Network (CF-TDN). Note: approaches to class V (splicing mutations that alter surface CFTR levels), and class VI (mutations in the PDZ binding domain that decrease surface stability and/or alter recycling) CFTR mutations are under development, but have not yet entered clinical testing through the TDN.